ICD-10-PCS Codes Deleted in
64 codes were deleted from the 2023 ICD-10-PCS code set, effective October 1, 2022.
Displaying codes 1-64 of 64:
-
5A0512C Extracorporeal Supersaturated Oxygenation, Intermittent
-
5A0522C Extracorporeal Supersaturated Oxygenation, Continuous
-
D0Y0KZZ Laser Interstitial Thermal Therapy of Brain
-
D0Y1KZZ Laser Interstitial Thermal Therapy of Brain Stem
-
D0Y6KZZ Laser Interstitial Thermal Therapy of Spinal Cord
-
D0Y7KZZ Laser Interstitial Thermal Therapy of Peripheral Nerve
-
DBY0KZZ Laser Interstitial Thermal Therapy of Trachea
-
DBY1KZZ Laser Interstitial Thermal Therapy of Bronchus
-
DBY2KZZ Laser Interstitial Thermal Therapy of Lung
-
DBY5KZZ Laser Interstitial Thermal Therapy of Pleura
-
DBY6KZZ Laser Interstitial Thermal Therapy of Mediastinum
-
DBY7KZZ Laser Interstitial Thermal Therapy of Chest Wall
-
DBY8KZZ Laser Interstitial Thermal Therapy of Diaphragm
-
DDY0KZZ Laser Interstitial Thermal Therapy of Esophagus
-
DDY1KZZ Laser Interstitial Thermal Therapy of Stomach
-
DDY2KZZ Laser Interstitial Thermal Therapy of Duodenum
-
DDY3KZZ Laser Interstitial Thermal Therapy of Jejunum
-
DDY4KZZ Laser Interstitial Thermal Therapy of Ileum
-
DDY5KZZ Laser Interstitial Thermal Therapy of Colon
-
DDY7KZZ Laser Interstitial Thermal Therapy of Rectum
-
DDY8KZZ Laser Interstitial Thermal Therapy of Anus
-
DFY0KZZ Laser Interstitial Thermal Therapy of Liver
-
DFY1KZZ Laser Interstitial Thermal Therapy of Gallbladder
-
DFY2KZZ Laser Interstitial Thermal Therapy of Bile Ducts
-
DFY3KZZ Laser Interstitial Thermal Therapy of Pancreas
-
DGY0KZZ Laser Interstitial Thermal Therapy of Pituitary Gland
-
DGY1KZZ Laser Interstitial Thermal Therapy of Pineal Body
-
DGY2KZZ Laser Interstitial Thermal Therapy of Adrenal Glands
-
DGY4KZZ Laser Interstitial Thermal Therapy of Parathyroid Glands
-
DGY5KZZ Laser Interstitial Thermal Therapy of Thyroid
-
DMY0KZZ Laser Interstitial Thermal Therapy of Left Breast
-
DMY1KZZ Laser Interstitial Thermal Therapy of Right Breast
-
DVY0KZZ Laser Interstitial Thermal Therapy of Prostate
-
X2RF032 Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Open Approach, New Technology Group 2
-
X2RF332 Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Approach, New Technology Group 2
-
X2RF432 Replacement of Aortic Valve using Zooplastic Tissue, Rapid Deployment Technique, Percutaneous Endoscopic Approach, New Technology Group 2
-
XHRPXL2 Replacement of Skin using Porcine Liver Derived Skin Substitute, External Approach, New Technology Group 2
-
XK02303 Introduction of Concentrated Bone Marrow Aspirate into Muscle, Percutaneous Approach, New Technology Group 3
-
XRG0092 Fusion of Occipital-cervical Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG00F3 Fusion of Occipital-cervical Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG1092 Fusion of Cervical Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG10F3 Fusion of Cervical Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG2092 Fusion of 2 or more Cervical Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG20F3 Fusion of 2 or more Cervical Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG4092 Fusion of Cervicothoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG40F3 Fusion of Cervicothoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG6092 Fusion of Thoracic Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG60F3 Fusion of Thoracic Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG7092 Fusion of 2 to 7 Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG70F3 Fusion of 2 to 7 Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRG8092 Fusion of 8 or more Thoracic Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRG80F3 Fusion of 8 or more Thoracic Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRGA092 Fusion of Thoracolumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRGA0F3 Fusion of Thoracolumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRGB092 Fusion of Lumbar Vertebral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRGB0F3 Fusion of Lumbar Vertebral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRGC092 Fusion of 2 or more Lumbar Vertebral Joints using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRGC0F3 Fusion of 2 or more Lumbar Vertebral Joints using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XRGD092 Fusion of Lumbosacral Joint using Nanotextured Surface Interbody Fusion Device, Open Approach, New Technology Group 2
-
XRGD0F3 Fusion of Lumbosacral Joint using Radiolucent Porous Interbody Fusion Device, Open Approach, New Technology Group 3
-
XW03392 Introduction of Defibrotide Sodium Anticoagulant into Peripheral Vein, Percutaneous Approach, New Technology Group 2
-
XW033A3 Introduction of Bezlotoxumab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 3
-
XW04392 Introduction of Defibrotide Sodium Anticoagulant into Central Vein, Percutaneous Approach, New Technology Group 2
-
XW043A3 Introduction of Bezlotoxumab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 3
